Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab and FeNO in Multiple Food Allergies
NCT06437171Phase 4Completed
- Sponsor
- AAADRS Clinical Research Center
- Start
- Jun 2024
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of omalizumab in food allergy, sponsored by AAADRS Clinical Research Center. Primary endpoint: Change in Exhaled Nitric Oxide (FeNO) from baseline at 52 weeks. Started Jun 2024; status: completed.
02
Drugs
omalizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT06437171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437171.